Novartis Pharmaceuticals received a voluntary dismissal of claims from plaintiffs for their bisphosphonate drug in the midst of a trial. Novartis manufactures and sells Zometa, a drug indicated to strengthen bone in cancer patients whose disease has metastasized to bone.
Our firm served as lead trial counsel in the case. This was one of hundreds of similar cases against Novartis ongoing across the country. Brown v. Novartis Pharmaceuticals Corp., No. 7:08-cv-00130-FL (E.D. NC 2012)